Hyep Ivan
SEC CIK 2034668 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | CFO | 142.4K | — | $3.24M | 22 | 2025-10-06 | 2026-08-10 |
Most active insiders at BCAX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | $4.80M | — |
| 2 | Cohlhepp Ryan | Pres, COO, Interim CEO, Dir | — | $4.60M |
| 3 | Mazumdar Claire | CEO, Dir | — | $4.06M |
| 4 | Hyep Ivan | CFO | — | $3.24M |
| 5 | Raben David | Chief Medical Off | — | $1.15M |
| 6 | Meisner Lara | CLO | — | $498.7K |
Transactions 22
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-12 16:19 | 2026-08-10 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | M - OptEx | $3.79 | +12.5K | 142.4K | +10% | +$47.4K |
| DT | 2026-08-12 16:19 | 2026-08-10 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $27.97 | -12.5K | 129.9K | -9% | -$349.6K |
| DT | 2026-07-10 16:10 | 2026-07-08 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | M - OptEx | $3.79 | +12.5K | 157.9K | +9% | +$47.4K |
| DMT | 2026-07-10 16:10 | 2026-07-08 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $28.85 | -28.0K | 129.9K | -18% | -$807.7K |
| DT | 2026-05-26 17:48 | 2026-05-21 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | M - OptEx | $3.79 | +9,200 | 154.6K | +6% | +$34.9K |
| DT | 2026-05-26 17:48 | 2026-05-21 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $20.42 | -9,200 | 145.4K | -6% | -$187.9K |
| DT | 2026-04-22 16:53 | 2026-04-21 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | M - OptEx | $3.79 | +9,200 | 154.6K | +6% | +$34.9K |
| DT | 2026-04-22 16:53 | 2026-04-21 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $23.00 | -9,200 | 145.4K | -6% | -$211.6K |
| D | 2026-03-24 | 2026-03-23 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | M - OptEx | $3.79 | +9,200 | 154.6K | +6% | +$34.9K |
| D | 2026-03-24 | 2026-03-23 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.52 | -9,200 | 145.4K | -6% | -$170.4K |
| DM | 2026-03-05 | 2026-03-03+ | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.23 | -16.5K | 145.4K | -10% | -$301.0K |
| DM | 2026-03-05 | 2026-03-03+ | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | M - OptEx | $3.79 | +16.5K | 152.7K | +12% | +$62.6K |
| D | 2026-01-26 | 2026-01-22 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | M - OptEx | $3.79 | +1,882 | 147.2K | +1% | +$7,133 |
| D | 2026-01-26 | 2026-01-22 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.15 | -1,882 | 145.4K | -1% | -$34.2K |
| D | 2025-12-23 | 2025-12-22 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | M - OptEx | $3.79 | +9,200 | 154.6K | +6% | +$34.9K |
| D | 2025-12-23 | 2025-12-22 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.31 | -9,200 | 145.4K | -6% | -$168.5K |
| DM | 2025-11-25 | 2025-11-21+ | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | M - OptEx | $3.79 | +18.4K | 163.2K | +13% | +$69.7K |
| DM | 2025-11-25 | 2025-11-21+ | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.54 | -18.4K | 145.4K | -11% | -$341.1K |
| D | 2025-10-10 | 2025-10-09 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | M - OptEx | $3.79 | +6,415 | 151.8K | +4% | +$24.3K |
| D | 2025-10-10 | 2025-10-09 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.23 | -6,415 | 145.4K | -4% | -$116.9K |
| DM | 2025-10-08 | 2025-10-06+ | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.21 | -30.4K | 145.4K | -17% | -$553.2K |
| DM | 2025-10-08 | 2025-10-06+ | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | M - OptEx | $3.79 | +30.4K | 151.9K | +25% | +$115.2K |
Purchase Sale Sale after option exercise All abbreviations